Table 1S. Additional materials and methods. Sample

0 downloads 0 Views 159KB Size Report
acquired with a Navios flow-cytometry (Beckman Coulter, USA). For IHC antibodies anti-CD8 were from Thermo Scientific, USA, and anti CD20 from Novocastra, ...
Table 1S. Additional materials and methods. Sample selection process Sample selection flow-chart used for both cohorts, numbers refer to the identification cohort samples. 527 samples 21 healthy controls after aHSCT, from 81 patients 235 samples excluded: < 5% CD19+ cells in peripheral blood* or poor quality samples 292 samples 176 GVHD+ samples from 44 patients 136 samples excluded: GVHD onset >150 days before sampling# 7 samples excluded: concomitant infections 33 GVHD+ samples from 20 patients

Restriction to 1 sample/patient: First access to clinic after GVHD onset

21 healthy controls

Allocation

116 GVHD- samples from 33 patients

80 samples excluded: - concomitant infections - previous GVHD/suspected GVHD

36 GVHD- samples from 15 patients

Restriction to 1 sample/patient: First access to clinic after aHSCT

20 GVHD+ patients

15 GVHD- patients

Legend *In the verification cohort samples with